precision_logo.jpg
Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference
04 janv. 2021 07h00 HE | Precision Biosciences
DURHAM, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
precision_logo.jpg
Precision BioSciences Announces Executive Leadership Change
14 déc. 2020 00h00 HE | Precision Biosciences
DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
precision_logo.jpg
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
04 déc. 2020 06h30 HE | Precision Biosciences
Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS), and No Grade ≥ 3 Neurotoxicity (ICANS) PBCAR0191...
precision_logo.jpg
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
24 nov. 2020 16h05 HE | Precision Biosciences
DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
precision_logo.jpg
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update
10 nov. 2020 07h00 HE | Precision Biosciences
Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors Advanced CAR T clinical pipeline, including a clinical...
precision_logo.jpg
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
03 nov. 2020 07h00 HE | Precision Biosciences
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
precision_logo.jpg
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
15 oct. 2020 07h00 HE | Precision Biosciences
DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Alex_Kelly_Precision_Biosciences_0019_Color_Web
Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer
14 oct. 2020 07h00 HE | Precision Biosciences
DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
precision_logo.jpg
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
28 sept. 2020 07h00 HE | Precision Biosciences
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
precision_logo.jpg
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
21 sept. 2020 07h00 HE | Precision Biosciences
DURHAM, N.C. and STAMFORD, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene...